iShares Biotechnology ETF
IBB
iShares Biotechnology ETF IBB Strategy
The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector.
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
The investment objective & strategy is a summary of the investment's principal strategy as written in the prospectus. This information is pulled from the most recent product disclosure document.
ETFs News & Analysis
etfs
Young & Invested: Why this popular ETF might not be the best way to access the market
Investors often assume the cheapest ETF is the best option, but that may not be the case in one corner of the Australian market.
etfs
Young & Invested: Do you need both IVV and NDQ in your portfolio?
A closer look at the illusion of choice in a concentrated market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,922.70 | 11.80 | 0.13% |
| CAC 40 | 8,121.44 | 65.49 | -0.80% |
| DAX 40 | 25,543.87 | 172.84 | -0.67% |
| Dow JONES (US) | 51,778.04 | 316.14 | 0.61% |
| FTSE 100 | 10,726.80 | 89.34 | -0.83% |
| HKSE | 24,750.78 | 146.49 | 0.60% |
| NASDAQ | 26,418.30 | 439.87 | 1.69% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,739.14 | 17.45 | -0.13% |
| S&P 500 | 7,637.76 | 85.95 | 1.14% |
| S&P/ASX 200 | 8,731.20 | 1.20 | -0.01% |
| SSE Composite Index | 3,911.87 | 36.27 | 0.94% |